Nanotechnology Now - Press Release: NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company

Home > Press > NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company

Abstract:
NanoMaterials Technology ("NMT") announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.

NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company

SINGAPORE | Posted on October 25th, 2007

As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.

"Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance," says Dr Jimmy Yun, the CEO of NMT. NMT's niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.

NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board ("SAB").

John Mitchell retired from Pfizer Inc as Senior Vice President and President/Team Leader, Pfizer Global Manufacturing at the end of 2004. While at Pfizer, he was responsible for worldwide manufacturing operations that produced pharmaceutical, consumer healthcare and animal health products, encompassing plants and logistics centers at more than 120 sites in 40 countries.

John holds a Bachelor of Engineering degree from Yale University and an honorary Doctor of Laws degree from the National University of Ireland.

Prof. Neumann is currently a Senior Consultant of R&D at Merck KGaA. At Merck KGaA, Prof. Neumann was a group leader in R&D in the Diagnostic Division until 1985. He subsequently headed up the Immunochemistry Department in Preclinical Research at Merck Pharma until 1989 when he returned as the Head of R&D of the Diagnostic Division. In 1994, he moved on to head up the Business Development and Research Alliance Office in Specialty Chemistry and Biotechnology. Prof. Neumann has an established track record in technology scouting and evaluation, and participates in various national and international expert panels in the field of biotechnology.

Prof. Neumann received his PhD in biochemistry from the University of Bochum, Germany in 1971.

"It is a great pleasure and honour for us to have both John and Prof. Neumann joining our SAB. Their addition to our SAB is invaluable as they bring with them broad and in-depth experience in the pharmaceutical industry," says Dr. Yun.

####

About NanoMaterials Technology ("NMT")
Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specialises in the development and commercialisation of the production technologies of nanomaterials.

NMT has a proprietary technology called the High Gravity Controlled Precipitation (HGCP). The result of this breakthrough is a nanomaterial production technology that is simple, easy to scale up and extremely cost effective.

For more information, please click here

Contacts:
NanoMaterials Technology Pte Ltd
Ms Grace Yeo
Tel: +65-9384-1818
Email:

Cogent Communications Pte Ltd
Ms Celine Ooi
Tel: +65-6323-1060
Email:

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: